Veterinary Pain Management Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Veterinary Pain Management Market Trends and Insights

Rising Pet Ownership & Humanization

Pet owners increasingly expect human-level clinical standards, prompting premium adoption of innovations such as Zoetis’ bedinvetmab injections. The American Animal Hospital Association’s 2024 guidelines codify multimodal regimens, legitimizing antibody use alongside NSAIDs. Retailers of welfare-certified livestock products likewise seek credible analgesia claims to justify price premiums, widening overall demand.

Growing Osteoarthritis & Post-Operative Pain Incidence

Osteoarthritis affects 20% of dogs older than one year and nearly 90% of cats above 12 years. FDA approval of bedinvetmab established biologics as viable long-term solutions, with trial success rates of 43.5% versus 16.9% for placebo. Long-acting bupivacaine formulations such as Elanco’s Nocita deliver 72-hour coverage, curbing readmission rates and owner burden. Productivity losses in untreated livestock further amplify the economic argument for effective analgesia.

Expansion of Livestock Welfare Regulations

The European Union’s 2024 rules oblige analgesia during dehorning, castration, and tail docking, with fines for non-compliance. The United States Department of Agriculture increased inspection frequencies 40% since 2023, pressuring producers to adopt label-approved drugs over off-label low-cost options. Such mandates convert compliance costs into recurring revenue streams for suppliers.

Mandatory Multimodal Analgesia Protocols (EU, US)

European Medicines Agency guidance insists veterinarians justify high-dose monotherapies, nudging clinics toward combination approaches and device adjuncts. Companies possessing both drug and device assets can therefore bundle solutions, whereas single-product firms must forge partnerships or broaden their pipelines.

Adverse-Event Profile of NSAIDs & Opioids

Veterinarians weigh renal, hepatic, and gastrointestinal risks when prescribing NSAIDs, and diversion concerns complicate opioid dispensing. Post-marketing surveillance of bedinvetmab documented 17,162 adverse reports from 18 million doses, reminding clinicians that even innovative biologics carry safety obligations. FDA approval of suzetrigine for human use underscores momentum toward non-opioid classes that may cross into veterinary care.

Stringent Regulatory Approval Timelines

Average review cycles exceed five years, and combination products require parallel device and drug dossiers, lifting costs above USD 10 million. VICH streamlining efforts have yielded uneven national adoption, compelling companies to fund multiple submissions or delay market entry.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Devices Gain Ground Despite Drug Dominance

The pharmaceutical segment captured 81.05% of the veterinary pain management market size in 2025, anchored by NSAIDs such as meloxicam, yet device revenues are growing at a 6.03% CAGR. NSAIDs persist as first-line therapy because of cost efficiency, whereas opioid use retreats under diversion scrutiny. Long-acting local anesthetics like Nocita extend analgesia to 72 hours and mitigate readmission. Alpha-2 agonists retain niche roles in large animal sedation. Early cannabinoid entrants address chronic pain that resists conventional classes, despite regulatory headwinds.  

Portable diode-laser units, PEMF mats, and shockwave systems are carving out space as stand-alone or adjunct solutions. Clinics promote these technologies for geriatric pets intolerant of NSAIDs, while equine practitioners leverage PEMF for musculoskeletal recovery. Manufacturers now bundle software analytics that log session parameters, enabling veterinarians to document compliance with multimodal mandates. The device trajectory signals that the veterinary pain management market will increasingly balance pharmacology with non-pharmacologic modalities.

By Animal Type: Companion Animals Drive Future Growth

Livestock held 55.31% of the veterinary pain management market share in 2025, reflecting mandatory compliance across large herds. Nevertheless, the companion segment is projected to expand at 6.78% CAGR, lifted by a global pet economy valued at USD 261 billion. Livestock buyers emphasize cost-per-head and withdrawal periods, favoring proven molecules in bulk packaging. Conversely, dog and cat owners fund antibody injections and laser packages that prioritize quality of life over minimum viable care.  

Breakthrough NGF-targeting antibodies Librela and Solensia showcase pet-owner willingness to pay USD 75–115 monthly, pushing lifetime value per patient higher than typical NSAID regimes. Livestock producers are integrating automated dosing units to comply with welfare audits without inflating labor costs, indicating an efficiency-driven adoption model separate from the emotionally motivated companion sector.

By End User: Homecare Settings Emerge as Growth Driver

Hospitals and clinics accounted for 53.21% of revenue in 2025, yet homecare channels are accelerating at a 6.46% CAGR. Teleconsult platforms permit real-time video triage, and courier services deliver refill packs within hours. Transdermal buprenorphine (ZORBIUM) and chewable NSAIDs create regimens owners can administer without clinic visits. Monitoring apps link wearable activity trackers to veterinarian dashboards, flagging deviations that may indicate breakthrough pain. For chronic conditions, subscription models bundle monthly antibody injections, AI-powered pain-scoring assessments, and periodic telecheckups. Clinics retain a supervisory role but shift toward consultancy rather than direct administration, realigning revenue from procedure fees to service packages.

Academic and research institutes, while modest in revenue, furnish critical validation for new modalities. Universities refine feline grimace scales via machine learning and map cannabinoid pharmacokinetics in species-specific studies. Collaborative grants between universities and manufacturers fast-track concept-to-clinic timelines, reducing commercial risk. 

Geography Analysis

North America contributed 41.78% of global revenue in 2025, underpinned by high pet insurance penetration and a regulatory climate that enables rapid first-to-market approvals. Monoclonal antibody pioneers capitalized on FDA review efficiencies, securing early brand recognition. Canada’s cautious stance on controlled substances has, however, catalyzed investment in non-opioid drugs and cannabinoid research pipelines.

Europe follows closely, shaped by some of the world’s strictest welfare legislation. Mandatory multimodal analgesia elevates demand for diverse product kits, pushing suppliers to hold broader formularies. Antimicrobial stewardship programs restrain NSAID courses, indirectly prompting uptake of laser and electromagnetic therapy devices. The United Kingdom’s post-Brexit regulatory autonomy is allowing accelerated pathways for niche products, giving smaller firms an entry door ahead of pan-EU approvals.

Asia-Pacific is the fastest-expanding region with a projected 7.18% CAGR. Urban pet ownership in China rose sharply after pandemic-era lifestyle shifts, while Japan’s aging pet cohort parallels that of Western markets. South Korea’s reform of its Animal Protection Act stipulates pain relief during cosmetic surgery and disease treatment, creating new baseline demand. Emerging Southeast Asian economies deploy welfare upgrades to align with export certification criteria, translating policy into accessible market volume for globally established brands.

Regulatory Landscape

Regulation of veterinary pain therapies focuses on drug authorization, controlled-substance handling, and food-animal residue limits. In the European Union, Regulation (EU) 2019/6 governs authorization, distribution, and pharmacovigilance for veterinary medicinal products across Member States and EEA-aligned markets, shaping post-market safety reporting requirements relevant to NSAIDs, opioids, and newer biologics. The European Medicines Agency (EMA) also implemented guidance effective May 1, 2025 on efficacy and target-animal safety data requirements for certain non-immunological products intended for limited markets, creating a defined pathway for niche indications.

In the United States, the FDA Center for Veterinary Medicine (CVM) regulates new animal drugs under the FD&C Act via NADA/ANADA processes, and the agency updated animal drug regulations in January 2025 to reflect approval actions. Opioid stewardship is tightening through professional model guidance such as the American Association of Veterinary State Boards (AAVSB) 2026 model documents, which recommend limiting initial opioid prescriptions for acute pain to a 14-day supply with re-evaluation for continued need. For food-producing animals, EMA actions in 2025 to extend maximum residue limits (MRLs) for select substances reinforce the need for label-aligned use and compliance documentation in livestock analgesia protocols.

Value Chain Analysis

The veterinary pain management value chain starts with active pharmaceutical ingredients (APIs) and biologic raw materials, then moves through formulation and fill-finish (including sterile injectables and monoclonal antibodies). It then proceeds to quality release and regulatory compliance, followed by distribution to veterinary hospitals and clinics, retail and e-commerce pharmacies, and, increasingly, homecare fulfillment linked to telemedicine. Biologics and certain injectable products add complexity through validated cold-chain requirements, which raises the role of specialized temperature-controlled logistics providers and clinic-level storage controls.

Manufacturing scale and compliant distribution networks influence product availability and launch cadence across regions. Large suppliers such as Zoetis operate broad manufacturing and supply footprints (including dozens of global centers) that support multi-country launches and replenishment, while smaller innovators often rely on external manufacturing and staged regulatory routes. On the market access side, regulatory events in 2026 highlight multiple entry points: the UK Veterinary Medicines Directorate approval of Zoetis Lenivia (izenivetmab) and FDA conditional approval for Pegasus/PRN Pharmacal Liavium-CA1 (pregabalin) show how country-specific authorizations and conditional pathways feed downstream wholesaler onboarding, clinic formulary inclusion, and education-driven adoption. Device modalities (laser, PEMF, shockwave) follow a parallel chain from OEM manufacturing and software updates to clinic installation, training, and service contracts, with increasing emphasis on session logging to support multimodal protocol documentation.

Market Opportunities and Future Outlook

White space persists in long-acting, drug-sparing regimens for chronic osteoarthritis and neuropathic pain, especially where adverse-event concerns and opioid stewardship narrow prescribing flexibility. In 2026, Zoetis expanded the geographic availability of canine osteoarthritis biologics with Lenivia (izenivetmab) approvals and launches, illustrating clinic demand for longer dosing intervals and differentiated efficacy profiles versus legacy NSAIDs. At the same time, FDA conditional approval of Liavium-CA1 (pregabalin chewable tablets) for dogs with Chiari-like malformation and syringomyelia points to labeled neuropathic pain options that reduce reliance on off-label protocols while sponsors collect additional effectiveness data.

Non-pharmacologic modalities and data-enabled pain assessment provide a second commercialization lane, supported by multimodal analgesia practices and owner demand for at-home or clinic-packaged therapies. The 2026 launch of Enovis Companion Animal Health CT-RevitL, which incorporates intelligent treatment guidance, highlights product development aimed at standardized dosing and repeatable clinical workflows for laser therapy. Pipeline activity in disease-modifying osteoarthritis approaches also widens the opportunity set: VetrixBio disclosed 2026 clinical data for a bispecific antibody program (VTX-304) targeting both pain (NGF) and joint pathology (ADAMTS-5), positioning pain relief alongside cartilage protection as a differentiation axis. In livestock, academic findings that single-modality NSAID interventions can leave residual physiological stress in piglets reinforce demand for validated multi-modal protocols and administration-friendly formats that fit welfare audit requirements.